Sugentech (253840) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sugentech (253840) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩60.5B, trading at ₩3960.00 on the KOE. This SniperIQ fundamentals page covers Sugentech's valuation, profitability (net margin -247.8%), revenue (₩9.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sugentech's market cap?
Sugentech (253840) has a market capitalization of approximately ₩60.5B, trading at ₩3960.00 on the KOE. Market cap moves with the live share price.
What is Sugentech's P/E ratio?
Sugentech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sugentech?
Sugentech runs a net profit margin of -247.8%, a gross margin of 5.8%, and an operating margin of -197.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sugentech generate?
Sugentech reported revenue of ₩9.4B for fiscal year 2025, with net income of -₩23.3B and earnings per share (EPS) of -1403.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sugentech pay a dividend?
Sugentech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sugentech financially healthy?
Sugentech carries a debt-to-equity ratio of 0.20x and a current ratio of 10.82x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sugentech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sugentech (253840) the key facts are: market cap ₩60.5B, revenue ₩9.4B, 52-week range 3530-8670. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sugentech's full fundamentals live
Get Sugentech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.